Development of Prodrug Approaches for Long-Acting Injectable Nanoformulations of Emtricitabine-Based Regimens
Embargo until
2022-12-01
Date
2018-08-27
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Johns Hopkins University
Abstract
Most current antiretroviral (ARV) medications for HIV treatment and prevention necessitate lifelong daily dosing, and require high levels of patient adherence to be effective. Long-acting injectable (LAI) ARVs would allow less frequent administration, improving adherence. While nanomilled solid drug nanoparticles (SDNs) displaying long-acting delivery of ARVs following intramuscular injection are reported, technologies currently used to produce LAI-ARVs are incompatible with the nucleos(t)ide reverse transcriptase inhibitors (NRTIs) due to their high water solubility. It is critical to overcome this challenge to development of LAI NRTI strategies as most current ARV combination therapies include NRTI backbone therapies. Our long-term goal is to develop LAI-ARV approaches using lipophilic NRTI prodrugs. These pro-moieties will decrease NRTI water solubility and improve compatibility for SDN formation by the proprietary emulsion templated/freeze drying (ETFD) approach developed at the University of Liverpool.
To achieve this goal, I have designed and synthesized a variety of different prodrug strategies for the NRTI emtricitabine (FTC), a cytosine analog. My thesis research has explored the use of amino-masking groups, including carbamates, imines, and self-immolative strategies (trimethyl lock amide, and 4-alkyloxybenzyloxy), as well as 5’-hydroxyl masking groups, including carbonates and esters to decrease NRTI aqueous solubility. Prodrug activation kinetics were assessed in vitro via HPLC in human muscle, plasma, and liver fractions. Prodrugs were then screened for SDN compatibility via ETFD at the University of Liverpool. The most promising hits to emerge from these initial screens were then carried forward for screens at higher drug loading. Successful formulations emerging from these advanced screens were then used for preclinical PK studies in animal models, guided by in silico physiologically-based pharmacokinetic (PBPK) modeling.
Carbamate-based FTC prodrugs demonstrated the feasibility of our prodrug approach. Carbamates bearing longer alkyl chains (C7 and C8) were most efficiently activated in all conditions, with hydrolysis rates in liver higher than those in plasma or muscle. Carbonate moieties at the 5’-position were hydrolyzed more efficiently than the carbamate moiety under all conditions. Structure-activity relationship studies at the 5’-OH of the octyl carbamate FTC prodrug demonstrated a tolerance for branching in close proximity to the core of the molecule by esterases responsible for prodrug cleavage. However, increasing the distance between the site of cleavage and the site of branching decreased the efficiency of cleavage. Nanoparticle screening at 10 wt% prodrug demonstrated a correlation between calculated logP and the number of hits obtained. LogP also correlated with the ability to form SDNs with higher drug loading, with a hit for an octyl carbamate/carbonate FTC prodrug SDN achieved at 70 wt. %. In vivo studies demonstrated that higher-loaded prodrug SDNs can provide plasma exposure of FTC in rats for up to 14 days. Taken together, this work suggests that carbamate-based prodrug approaches offer a promising starting point for development of LAI FTC toward a complete LAI-ARV regimen to improve adherence.
Description
Keywords
HIV, long-acting, NRTI, emtricitabine, prodrug, nanoparticles